Contact

All Stories

  1. Molecular pathogenesis—Part B

    Article • January 2026, Elsevier

    Professor Nigel James Temperton

  2. Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccine

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  3. Serological evidence of SARS-CoV-2 infection in red and fallow deer in Great Britain.

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  4. Dipeptidase 1 is a functional receptor for a porcine coronavirus

    Article • Nature Microbiology, October 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  5. A Novel dual Influenza virus and SARS-CoV-2 neutralisation assay

    Article • September 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  6. Immunogenicity and Efficacy of Digitally Immune Optimised H1N1 Vaccine Candidates in Swine and Murine Animal Models

    Article • September 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  7. Divergent antibody-mediated population immunity to H5, H7 and H9 subtype potential pandemic influenza viruses

    Article • September 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  8. Natural infection and vaccination interact to shape Fc-mediated immunity against SARS-CoV-2

    Article • September 2025, Wiley

    Professor Nigel James Temperton

  9. Investigating factors driving shifts in subtype dominance within H5Nx clade 2.3.4.4b high pathogenicity avian influenza viruses

    Article • Journal of General Virology, September 2025, Society for General Microbiology

    Professor Nigel James Temperton

  10. Differential modulation of SARS-CoV-2 infection by complement factor H and properdin

    Article • Frontiers in Immunology, August 2025, Frontiers

    Professor Nigel James Temperton

  11. Cross-Neutralizing Monoclonal Antibodies with Broad Activity Against Human and Bat-Derived SARS-Related Coronaviruses

    Article • August 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  12. Development and optimisation of Influenza C and Influenza D pseudotyped viruses

    Article • Journal of Virological Methods, August 2025, Elsevier

    Professor Nigel James Temperton

  13. Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron

    Article • Cell Communication and Signaling, July 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  14. SARS-CoV-2 and its S protein activate the ability of the infected cells to escape immune attack

    Article • Frontiers in Immunology, June 2025, Frontiers

    Professor Nigel James Temperton

  15. Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses

    Article • Emerging Microbes & Infections, June 2025, Taylor & Francis

    Professor Nigel James Temperton

  16. Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity

    Article • npj Vaccines, May 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  17. Development and optimisation of Influenza C and Influenza D pseudotyped viruses

    Article • May 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton, Professor Janet M Daly

  18. Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD

    Article • Emerging Microbes & Infections, May 2025, Taylor & Francis

    Professor Nigel James Temperton

  19. Compartmentalised mucosal and blood immunity to SARS-CoV-2 is associated with high seroprevalence before the Delta wave in Africa

    Article • Communications Medicine, May 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  20. Digitally Immune-Optimised Next-Generation Influenza Vaccine Provides Cross-Clade Protection Against Emerging H5Nx Viruses

    Article • May 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  21. Investigating Factors Driving Shifts in Subtype Dominance within H5Nx Clade 2.3.4.4b High-Pathogenicity Avian Influenza viruses

    Article • April 2025, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  22. Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection

    Article • Scientific Reports, April 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  23. Digitally Immune-Optimised Next-Generation Influenza H5Nx Vaccination Provides Protection with Broad Cross-Clade Neutralisation Against Global Threats

    Article • March 2025, Springer Science + Business Media

    Professor Nigel James Temperton

  24. Alternative splicing expands the antiviral IFITM repertoire in Chinese rufous horseshoe bats

    Article • PLoS Pathogens, December 2024, PLOS

    Professor Nigel James Temperton

  25. Cellular sialoglycans are differentially required for endosomal and cell-surface entry of SARS-CoV-2 in lung cell lines

    Article • PLoS Pathogens, December 2024, PLOS

    Professor Nigel James Temperton

  26. Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients

    Article • British Journal of Haematology, November 2024, Wiley

    Professor Nigel James Temperton

  27. Digitally immune optimised haemagglutinin with nanocage plug-and-display elicits broadly neutralising pan-H5 influenza subtype vaccine responses

    Article • November 2024, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  28. Serological analysis in humans in Malaysian Borneo suggests prior exposure to H5 avian influenza near migratory shorebird habitats

    Article • Nature Communications, October 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  29. Validation of a Lassa virus functional neutralisation assay.

    Article • F1000Research, October 2024, Faculty of 1000, Ltd.

    Professor Nigel James Temperton

  30. Compartmentalised mucosal and blood immunity to SARS-CoV-2 associated with high seroprevalence before Delta wave in Africa

    Article • October 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  31. A Transgenic Mouse With a Humanized B-Cell Repertoire Mounts an Antibody Response to Influenza Infection and Vaccination

    Article • The Journal of Infectious Diseases, September 2024, Oxford University Press (OUP)

    Professor Nigel James Temperton

  32. Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses

    Article • Cell Reports, September 2024, Elsevier

    Professor Nigel James Temperton

  33. Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia

    Article • Journal of Translational Medicine, August 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  34. Conference Report: LPMHealthcare Emerging Viruses 2023 (EVOX23): Pandemics—Learning from the Past and Present to Prepare for the Future

    Article • Pathogens, August 2024, MDPI AG

    Professor Nigel James Temperton

  35. Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia

    Article • July 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  36. Centenarians, semi and supercentenarians, COVID-19 and Spanish flu: a serological assessment to gain insight into the resilience of older centenarians to COVID-19

    Article • Immunity & Ageing, June 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  37. Cellular sialoglycans are differentially required for endosomal and cell-surface entry of SARS-CoV-2

    Article • June 2024, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  38. Evaluation of monkeypox‐ and vaccinia‐virus neutralizing antibodies before and after smallpox vaccination: A sero‐epidemiological study

    Article • Journal of Medical Virology, June 2024, Wiley

    Professor Nigel James Temperton

  39.  A validate and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA neutralising antibodies for vaccine development and comparison

    Article • F1000Research, May 2024, Faculty of 1000, Ltd.

    Professor Nigel James Temperton

  40. Centenarians, Semi and Supercentenarians, COVID-19 and Spanish Flu: a serological assessment to gain insight into the resilience of older centenarians to COVID- 19

    Article • May 2024, Research Square

    Professor Nigel James Temperton

  41. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity

    Article • Cell Reports Medicine, May 2024, Elsevier

    Professor Nigel James Temperton

  42. Mapping the interaction sites of human and avian influenza A viruses and complement factor H

    Article • Frontiers in Immunology, April 2024, Frontiers

    Professor Nigel James Temperton

  43. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

    Article • Nature Communications, April 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  44. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86

    Article • Nature Communications, March 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  45. B cell maturation restored ancestral germlines to control Omicron BA.2.86

    Article • March 2024, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  46. The antiviral potential of the antiandrogen enzalutamide and the viral‐androgen signaling interplay in seasonal coronaviruses

    Article • Journal of Medical Virology, March 2024, Wiley

    Professor Nigel James Temperton

  47. A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration

    Article • Scientific Reports, February 2024, Springer Science + Business Media

    Professor Nigel James Temperton

  48. Immunological insights into COVID-19 in Southern Nigeria

    Article • Frontiers in Immunology, January 2024, Frontiers

    Professor Nigel James Temperton

  49. Studying longitudinal neutralising antibody levels against Equid herpesvirus 1 in experimentally infected horses using a novel pseudotype based assay

    Article • Virus Research, January 2024, Elsevier

    Professor Nigel James Temperton

  50. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

    Article • December 2023, Research Square

    Professor Nigel James Temperton

  51. Alternative splicing expands the antiviral IFITM repertoire in Chinese horseshoe bats

    Article • December 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  52. The antiviral potential of the antiandrogen enzalutamide and the viral-androgen interplay in seasonal coronaviruses

    Article • November 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  53. Serological evidence of virus infection in Eidolon helvum fruit bats: implications for bushmeat consumption in Nigeria

    Article • Frontiers in Public Health, November 2023, Frontiers

    Professor Nigel James Temperton

  54. Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay

    Article • Journal of Visualized Experiments, November 2023, MyJove Corporation

    Professor Nigel James Temperton

  55. A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses

    Article • Nature Biomedical Engineering, September 2023, Springer Science + Business Media

    Professor Nigel James Temperton

  56. Virus neutralisation assays using pseudotype vs wildtype viruses

    Article • Frontiers in Immunology, September 2023, Frontiers

    Professor Nigel James Temperton

  57. Mapping the interaction sites of Influenza A viruses and human complement Factor H

    Article • September 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  58. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation

    Article • iScience, September 2023, Elsevier

    Professor Nigel James Temperton

  59. 52 Human factor H and properdin modulate SARS-CoV-2 infection in a complement-independent manner

    Article • Immunobiology, September 2023, Elsevier

    Professor Nigel James Temperton

  60. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice

    Article • European Journal of Pharmaceutics and Biopharmaceutics, September 2023, Elsevier

    Professor Nigel James Temperton

  61. Human complement Factor H and Properdin act as soluble pattern recognition receptors and differentially modulate SARS-CoV-2 Infection

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  62. Serological evidence of high pathogenicity virus infection inEidolon helvumfruit bats in Nigeria

    Article • June 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton, Prof Claude Sabeta

  63. Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein

    Article • Viruses, May 2023, MDPI AG

    Professor Nigel James Temperton, Ahmad Al Aiyan

  64. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

    Article • Scientific Reports, March 2023, Springer Science + Business Media

    Professor Nigel James Temperton

  65. Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

    Article • March 2023, Research Square

    Professor Nigel James Temperton

  66. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses.

    Article • Cell Reports, March 2023, Elsevier

    Professor Nigel James Temperton

  67. Differential T-cell and Antibody Responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in Patients with Immunodeficiencies

    Article • Journal of Allergy and Clinical Immunology Global, March 2023, Elsevier

    Professor Nigel James Temperton

  68. Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

    Article • Frontiers in Immunology, February 2023, Frontiers

    Professor Nigel James Temperton

  69. Efficient Viral Capture and Inactivation from Bioaerosols Using Electrostatic Precipitation

    Article • February 2023, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  70. Pseudotyped Viruses for Influenza

    Article • January 2023, Springer Science + Business Media

    Professor Nigel James Temperton

  71. Efficient Viral Capture and Inactivation From Bioaerosols Using Electrostatic Precipitation

    Article • January 2023, Elsevier

    Professor Nigel James Temperton

  72. Studying Longitudinal Neutralising Antibody Levels Against Equid Herpesvirus 1 in Experimentally Infected Horses Using a Novel Pseudotype Based Assay

    Article • January 2023, Elsevier

    Professor Nigel James Temperton

  73. Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms

    Article • Vaccines, December 2022, MDPI AG

    Professor Nigel James Temperton

  74. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria

    Article • Scientific Reports, December 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  75. Application and comparison of lyophilisation protocols to enhance stable long-term storage of filovirus pseudotypes for use in antibody neutralisation tests

    Article • Journal of Applied Microbiology, December 2022, Oxford University Press (OUP)

    Professor Nigel James Temperton

  76. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

    Article • December 2022, Research Square

    Professor Nigel James Temperton

  77. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

    Article • Cell Reports, December 2022, Elsevier

    Professor Nigel James Temperton

  78. SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

    Article • The Oncologist, November 2022, Oxford University Press (OUP)

    Professor Nigel James Temperton

  79. Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies

    Article • The Lancet Microbe, November 2022, Elsevier

    Professor Nigel James Temperton

  80. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis

    Article • Frontiers in Immunology, September 2022, Frontiers

    Professor Nigel James Temperton, Fernando REAL

  81. Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design

    Article • Vaccines, September 2022, MDPI AG

    Professor Nigel James Temperton

  82. Author Correction: Isolation of infectious Lloviu virus from Schreiber’s bats in Hungary

    Article • Nature Communications, September 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  83. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study

    Article • Journal of Infection, September 2022, Elsevier

    Professor Nigel James Temperton

  84. Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response

    Article • Cell Reports Methods, August 2022, Elsevier

    Professor Nigel James Temperton

  85. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation

    Article • Frontiers in Immunology, July 2022, Frontiers

    Professor Nigel James Temperton, Chandan Kumar

  86. Author Correction: SARS-CoV-2 evolution during treatment of chronic infection

    Article • Nature, July 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  87. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

    Article • Nature, July 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  88. Human seasonal coronavirus neutralisation and COVID‐19 severity

    Article • Journal of Medical Virology, June 2022, Wiley

    Professor Nigel James Temperton

  89. Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure

    Article • Science, June 2022, American Association for the Advancement of Science

    Professor Nigel James Temperton

  90. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

    Article • Cell, June 2022, Elsevier

    Professor Nigel James Temperton

  91. Comparison of lentiviral and vesicular stomatitis virus core SARS-CoV-2 pseudotypes and generation of a stable cell line for use in antibody neutralisation assays

    Article • Access Microbiology, May 2022, Society for General Microbiology

    Professor Nigel James Temperton

  92. Use of Equine Herpesvirus 1 glycoprotein pseudotyped lentiviral particles for the development of serological tests and assessment of lyophilisation for transport and storage

    Article • Access Microbiology, May 2022, Society for General Microbiology

    Professor Nigel James Temperton

  93. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

    Article • JCI Insight, May 2022, American Society for Clinical Investigation

    Professor Nigel James Temperton

  94. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  95. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro

    Article • Nature Communications, May 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  96. Human Surfactant Protein D Facilitates SARS-CoV-2 Pseudotype Binding and Entry in DC-SIGN Expressing Cells, and Downregulates Spike protein Induced Inflammation

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  97. Application and comparison of lyophilisation protocols to enhance stable long-term storage of filovirus pseudotypes for use in antibody neutralisation tests

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  98. Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients

    Article • Communications Biology, May 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  99. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

    Article • Cell, May 2022, Elsevier

    Professor Nigel James Temperton

  100. Isolation of infectious Lloviu virus from Schreiber’s bats in Hungary

    Article • Nature Communications, March 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  101. Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds

    Article • Frontiers in Immunology, March 2022, Frontiers

    Professor Nigel James Temperton

  102. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals

    Article • EBioMedicine, March 2022, Elsevier

    Professor Nigel James Temperton

  103. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients

    Article • PLOS One, February 2022, PLOS

    Professor Nigel James Temperton

  104. HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19

    Article • Immunology, February 2022, Wiley

    Professor Nigel James Temperton

  105. Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection

    Article • Thorax, February 2022, BMJ

    Professor Nigel James Temperton

  106. AutoPlate: Rapid Dose-Response Curve Analysis for Biological Assays

    Article • Frontiers in Immunology, February 2022, Frontiers

    Professor Nigel James Temperton

  107. Gene delivery of a single,structurally engineered Coronavirus vaccine antigen elicits SARS-CoV-2 Omicron and pan-Sarbecovirus neutralisation

    Article • January 2022, Research Square

    Professor Nigel James Temperton

  108. Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

    Article • Journal of Translational Medicine, January 2022, Springer Science + Business Media

    Professor Nigel James Temperton

  109. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

    Article • Cell Host & Microbe, January 2022, Elsevier

    Professor Nigel James Temperton

  110. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  111. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases

    Article • Frontiers in Immunology, November 2021, Frontiers

    Professor Nigel James Temperton

  112. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2

    Article • Nature, November 2021, Springer Science + Business Media

    Professor Nigel James Temperton

  113. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection

    Article • Frontiers in Immunology, November 2021, Frontiers

    Professor Nigel James Temperton

  114. Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens

    Article • Journal of General Virology, November 2021, Society for General Microbiology

    Professor Nigel James Temperton

  115. Endemic Seasonal Coronavirus Neutralisation and COVID-19 severity

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  116. Influenza A (N1-N9) and Influenza B (B/Vic and B/Yam) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine design

    Article • September 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  117. Evaluation of a pseudotype virus neutralisation test for measurement of equine influenza virus (EIV) antibody responses induced by vaccination and experimental infection

    Article • Equine Veterinary Journal, September 2021, Wiley

    Professor Nigel James Temperton

  118. Generation of EHV‐1 pseudotype virus for cell tropism studies and virus‐neutralising assays

    Article • Equine Veterinary Journal, September 2021, Wiley

    Professor Nigel James Temperton

  119. Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected Patients

    Article • August 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  120. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses

    Article • Viruses, August 2021, MDPI AG

    Professor Nigel James Temperton

  121. Reservoir host studies of Lloviu virus: first isolation, sequencing and serology in Schreiber’s bats in Europe

    Article • August 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  122. Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection

    Article • Vaccines, July 2021, MDPI AG

    Professor Nigel James Temperton, Prof Claude Sabeta

  123. Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study

    Article • The Lancet Microbe, July 2021, Elsevier

    Professor Nigel James Temperton

  124. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection

    Article • July 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  125. Detection of serum cross-reactive antibodies and memory response to SARS-CoV-2 in pre-pandemic and post-COVID-19 convalescent samples

    Article • The Journal of Infectious Diseases, June 2021, Oxford University Press (OUP)

    Professor Nigel James Temperton

  126. Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patients

    Article • June 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  127. Feasibility for SARS-CoV-2 Tests in the Hospital: An Exposure Analysis of Critical Control Points Approach

    Article • June 2021, Research Square

    Professor Nigel James Temperton

  128. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

    Article • Cell, June 2021, Elsevier

    Professor Nigel James Temperton

  129. Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK

    Article • The Lancet Microbe, June 2021, Elsevier

    Professor Nigel James Temperton

  130. Measuring SARS-CoV-2 VOC neutralisation

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  131. Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies

    Article • Frontiers in Immunology, May 2021, Frontiers

    Professor Nigel James Temperton

  132. Establishing correlates of immunity for SARS-CoV-2

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  133. Synthetic influenza viruses from all A and B subtypes for vaccine testing

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton, Prof Claude Sabeta

  134. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  135. Single Pfizer shot protects prior infected against variants.

    Article • Science, April 2021, American Association for the Advancement of Science

    Professor Nigel James Temperton

  136. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies

    Article • Viruses, April 2021, MDPI AG

    Professor Nigel James Temperton

  137. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

    Article • Nature, March 2021, Springer Science + Business Media

    Professor Nigel James Temperton, Dr Sarah E Jackson

  138. Using safe mimic viruses to study antibody responses after COVID infection or vaccination

    Article • Oxford Open Immunology, February 2021, Oxford University Press (OUP)

    Professor Nigel James Temperton

  139. SARS-CoV-2 evolution during treatment of chronic infection

    Article • Nature, February 2021, Springer Science + Business Media

    Professor Nigel James Temperton, Dr Sarah E Jackson

  140. Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display

    Article • Scientific Reports, February 2021, Springer Science + Business Media

    Professor Nigel James Temperton

  141. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

    Article • Cell, February 2021, Elsevier

    Professor Nigel James Temperton

  142. The antigenic anatomy of SARS-CoV-2 receptor binding domain

    Article • Cell, February 2021, Elsevier

    Professor Nigel James Temperton, Professor William s James

  143. Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines

    Article • Vaccines, January 2021, MDPI AG

    Professor Nigel James Temperton

  144. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  145. C4b Binding Protein Acts as an Innate Immune Effector Against Influenza A Virus

    Article • Frontiers in Immunology, January 2021, Frontiers

    Professor Nigel James Temperton

  146. SARS-CoV-2 Vaccination Elicits Unconventional IgM Specific Responses in Naïve and Previously COVID19-Infected Individuals

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Professor Nigel James Temperton, Donato Zipeto

  147. Fatal COVID-19 Outcomes are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Professor Nigel James Temperton

  148. Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes

    Article • BIO-PROTOCOL, January 2021, Bio-Protocol, LLC

    Professor Nigel James Temperton

  149. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

    Article • Science Immunology, December 2020, American Association for the Advancement of Science

    Professor Nigel James Temperton

  150. Convalescent plasma therapy for the treatment of patients with COVID ‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels

    Article • Transfusion Medicine, December 2020, Wiley

    Professor Nigel James Temperton

  151. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation

    Article • December 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  152. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens

    Article • Scientific Reports, December 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Professor Nigel James Temperton

  153. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

    Article • Nature Microbiology, October 2020, Springer Science + Business Media

    Professor Nigel James Temperton

  154. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020

    Article • Eurosurveillance, October 2020, European Centre for Disease Control and Prevention (ECDC)

    Professor Nigel James Temperton, Professor Ahilanandan Dushianthan

  155. Healthcare workers with mild / asymptomatic SARS-CoV-2 infection show T cell responses and neutralising antibodies after the first wave

    Article • October 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  156. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays

    Article • Viruses, September 2020, MDPI AG

    Professor Nigel James Temperton

  157. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant

    Article • Cell Reports Medicine, September 2020, Elsevier

    Professor Nigel James Temperton

  158. Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease

    Article • August 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  159. Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection

    Article • Vaccines, August 2020, MDPI AG

    Professor Nigel James Temperton, Professor Janet M Daly

  160. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

    Article • July 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  161. Influenza D pseudotyped lentiviruses: production, neutralisation assay and serological surveillance

    Article • Access Microbiology, July 2020, Society for General Microbiology

    Professor Nigel James Temperton

  162. Tropism and neutralisation studies on bat influenza H17N10

    Article • Access Microbiology, July 2020, Society for General Microbiology

    Professor Nigel James Temperton

  163. Generation of Equine Herpesvirus type 1 glycoprotein pseudotyped lentiviral particles for use as a tool for tropism and diagnostic studies

    Article • Access Microbiology, July 2020, Society for General Microbiology

    Professor Nigel James Temperton

  164. Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease

    Article • June 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  165. Feasibility for SARS-CoV-2 Tests in the Hospital: An Exposure Analysis of Critical Control Points Approach

    Article • June 2020, Research Square

    Professor Nigel James Temperton

  166. Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity

    Article • Frontiers in Immunology, May 2020, Frontiers

    Professor Nigel James Temperton

  167. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  168. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  169. ­­­The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Professor Nigel James Temperton

  170. A Promising MERS Vaccine for Camels

    Article • Scientific Reports, November 2019, Springer Science + Business Media

    Dr. Naif Khalaf Alharbi, Professor Nigel James Temperton

  171. Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor

    Article • Nature Microbiology, July 2019, Springer Science + Business Media

    Professor Nigel James Temperton

  172. Generation, lyophilisation and epitope modification of high titre filovirus pseudotyped lentiviruses for use in antibody neutralisation assays and ELISA

    Article • Access Microbiology, March 2019, Society for General Microbiology

    Professor Nigel James Temperton

  173. Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry

    Article • Viruses, February 2019, MDPI AG

    Professor Nigel James Temperton

  174. Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin

    Article • Antibodies, February 2019, MDPI AG

    Professor Nigel James Temperton

  175. Generation, lyophilisation and epitope modification of high titre filovirus pseudotyped lentiviruses for use in antibody neutralisation assays

    Article • International Journal of Infectious Diseases, February 2019, Elsevier

    Professor Nigel James Temperton

  176. The bat influenza H17N10 is neutralized by broadly-neutralizing monoclonal antibodies and its neuraminidase facilitates viral egress

    Article • International Journal of Infectious Diseases, February 2019, Elsevier

    Professor Nigel James Temperton

  177. The MHC class-II HLA-DR receptor mediates bat influenza A-like H17N10 virus entry into mammalian cells

    Article • January 2019, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  178. The bat influenza H17N10 can be neutralized by broadly-neutralizing monoclonal antibodies and its neuraminidase can facilitate viral egress.

    Article • December 2018, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  179. Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies

    Article • December 2018, Cold Spring Harbor Laboratory Press

    Professor Stefan Pöhlmann, Professor Nigel James Temperton

  180. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines

    Article • Frontiers in Immunology, October 2018, Frontiers

    Professor Nigel James Temperton

  181. A naturally protective epitope of limited variability as an influenza vaccine target

    Article • Nature Communications, September 2018, Springer Science + Business Media

    Professor Nigel James Temperton

  182. Production of lentiviral vectors pseudotyped with influenza neuraminidase (NA) v1 (protocols.io.rkkd4uw)

    Article • July 2018, ZappyLab, Inc.

    Professor Nigel James Temperton

  183. Cross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccines

    Article • May 2018, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  184. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens

    Article • Frontiers in Immunology, February 2018, Frontiers

    Professor Nigel James Temperton

  185. How to measure neutralising antibodies with pseudotypes - a practical guide.

    Article • Methods and Protocols, January 2018, MDPI AG

    Professor Nigel James Temperton

  186. Measuring the level of antibodies against influenza neuraminidase.

    Article • BIO-PROTOCOL, January 2018, Bio-Protocol, LLC

    Professor Nigel James Temperton

  187. Measuring the antibody response against influenza neuraminidase

    Article • November 2017, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  188. An epitope of limited variability as a novel influenza vaccine target

    Article • November 2017, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  189. The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays

    Article • Pathogens, September 2017, MDPI AG

    Professor Nigel James Temperton

  190. The use of hyperimmune chicken reference sera is not appropriate for the validation of influenza pseudotype neutralization assays

    Article • August 2017, Cold Spring Harbor Laboratory Press

    Professor Nigel James Temperton

  191. Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge

    Article • The Journal of Immunology, July 2017, The American Association of Immunologists

    Professor Nigel James Temperton

  192. Four potential vaccines developed against MERS-CoV tested in mice

    Article • Vaccine, June 2017, Elsevier

    Professor Nigel James Temperton, Dr. Naif Khalaf Alharbi

  193. Chimeric influenza haemagglutinins: Generation and use in pseudotype neutralization assays

    Article • MethodsX, January 2017, Elsevier

    Professor Nigel James Temperton

  194. Production of SARS coronavirus virus mimics for measurement of protective antibody levels.

    Article • BIO-PROTOCOL, January 2017, Bio-Protocol, LLC

    Professor Nigel James Temperton

  195. The Optimisation of Pseudotyped Viruses for the Characterisation of Immune Responses to Equine Influenza Virus

    Article • Pathogens, December 2016, MDPI AG

    Professor Nigel James Temperton, Professor Janet M Daly

  196. Exploiting viral pseudotypes for emerging virus research

    Article • International Journal of Infectious Diseases, December 2016, Elsevier

    Professor Nigel James Temperton

  197. The contribution of specific haemagglutinin mutations to equine influenza vaccine breakdown

    Article • Journal of Equine Veterinary Science, April 2016, Elsevier

    Professor Nigel James Temperton

  198. Optimisation of equine influenza pseudotyped virus production

    Article • Journal of Equine Veterinary Science, April 2016, Elsevier

    Professor Nigel James Temperton

  199. Stalking influenza by vaccination with pre-fusion headless HA mini-stem

    Article • Scientific Reports, March 2016, Nature

    Professor Nigel James Temperton

  200. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods

    Article • Journal of Controlled Release, March 2016, Elsevier

    Professor Nigel James Temperton

  201. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines

    Article • Vaccine, March 2016, Elsevier

    Professor Nigel James Temperton, Dr Muhammad Shamsher Ahmed

  202. Who are the Viral Pseudotype Unit, and what do they do ?

    Article • Future Virology, February 2016, Future Medicine

    Professor Nigel James Temperton

  203. Technical considerations for the generation of novel pseudotyped viruses

    Article • Future Virology, January 2016, Future Medicine

    Professor Nigel James Temperton, Professor Janet M Daly

  204. Ebolavirus: pseudotypes, libraries and standards

    Article • Future Virology, November 2015, Future Medicine

    Professor Nigel James Temperton

  205. Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody

    Article • Proceedings of the National Academy of Sciences, July 2015, Proceedings of the National Academy of Sciences

    Professor Nigel James Temperton

  206. Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype

    Article • Frontiers in Immunology, June 2015, Frontiers

    Professor Nigel James Temperton

  207. Taking viral pseudotypes out of the laboratory and into the clinic.

    Article • June 2015, Wiley

    Professor Nigel James Temperton

  208. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination

    Article • Vaccine, June 2015, Elsevier

    Professor Nigel James Temperton

  209. The application of pseudotypes to influenza pandemic preparedness

    Article • Future Virology, June 2015, Future Medicine

    Professor Nigel James Temperton

  210. Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses

    Article • Journal of General Virology, May 2015, Society for General Microbiology

    Professor Nigel James Temperton

  211. What are influenza pseudotypes and how can they be used ?

    Article • Frontiers in Immunology, April 2015, Frontiers

    Professor Nigel James Temperton

  212. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

    Article • F1000Research, February 2015, Faculty of 1000, Ltd.

    Professor Nigel James Temperton

  213. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection

    Article • Antiviral Research, February 2015, Elsevier

    Professor Nigel James Temperton, Dr Muhammad Shamsher Ahmed

  214. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

    Article • F1000Research, January 2015, Faculty of 1000, Ltd.

    Professor Nigel James Temperton

  215. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes

    Article • MethodsX, January 2015, Elsevier

    Professor Nigel James Temperton

  216. Freeze-drying pseudotype viruses for serology in resource-poor laboratories

    Article • Journal of Virological Methods, December 2014, Elsevier

    Professor Nigel James Temperton

  217. Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation

    Article • Journal of Biological Chemistry, October 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Nigel James Temperton

  218. Influenza vaccine serology

    Article • Vaccines, October 2014, MDPI AG

    Professor Nigel James Temperton

  219. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection

    Article • Proceedings of the National Academy of Sciences, June 2014, Proceedings of the National Academy of Sciences

    Professor Nigel James Temperton

  220. Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests

    Article • Infection Ecology & Epidemiology, January 2014, Taylor & Francis

    Professor Nigel James Temperton

  221. Multiplex Evaluation of Influenza Neutralizing Antibodies with Potential Applicability to In-Field Serological Studies

    Article • Journal of Immunology Research, January 2014, Hindawi Publishing Corporation

    Professor Nigel James Temperton

  222. Discordant Correlation between Serological Assays Observed When Measuring Heterosubtypic Responses against Avian Influenza H5 and H7 Viruses in Unexposed Individuals

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Professor Nigel James Temperton

  223. Chicken Interferon-Inducible Transmembrane Protein 3 Restricts Influenza Viruses and LyssavirusesIn Vitro

    Article • Journal of Virology, September 2013, ASM Journals

    Professor Nigel James Temperton

  224. Comparative Serological Assays for the Study of H5 and H7 Avian Influenza Viruses

    Article • Influenza Research and Treatment, September 2013, Wiley

    Professor Nigel James Temperton

  225. Current progress with serological assays for exotic emerging/re-emerging viruses

    Article • Future Virology, August 2013, Future Medicine

    Professor Nigel James Temperton, Professor Janet M Daly

  226. Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

    Article • European Journal of Immunology, June 2013, Wiley

    Professor Nigel James Temperton

  227. Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility

    Article • Journal of General Virology, March 2013, Society for General Microbiology

    Professor Nigel James Temperton

  228. Infection with 2009 H1N1 Influenza Virus Primes for Immunological Memory in Human Nose-Associated Lymphoid Tissue, Offering Cross-Reactive Immunity to H1N1 and Avian H5N1 Viruses

    Article • Journal of Virology, March 2013, ASM Journals

    Professor Nigel James Temperton

  229. The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses

    Article • Journal of Molecular and Genetic Medicine, January 2013, OMICS Publishing Group

    Professor Nigel James Temperton

  230. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes

    Article • Journal of Molecular and Genetic Medicine, January 2013, OMICS Publishing Group

    Professor Nigel James Temperton

  231. The use of equine influenza pseudotypes for serological screening

    Article • Journal of Molecular and Genetic Medicine, January 2012, OMICS Publishing Group

    Professor Nigel James Temperton

  232. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

    Article • Science, July 2011, American Association for the Advancement of Science

    Professor Nigel James Temperton

  233. Antigenic Drift in H5N1 Avian Influenza Virus in Poultry Is Driven by Mutations in Major Antigenic Sites of the Hemagglutinin Molecule Analogous to Those for Human Influenza Virus

    Article • Journal of Virology, July 2011, ASM Journals

    Professor Nigel James Temperton

  234. Faculty Opinions recommendation of Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

    Article • April 2011, F1000Research

    Professor Nigel James Temperton

  235. Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules

    Article • PLOS One, April 2011, PLOS

    Professor Nigel James Temperton, Xavier Saelens

  236. Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection

    Article • The Journal of Infectious Diseases, March 2011, Oxford University Press (OUP)

    Professor Nigel James Temperton

  237. Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines

    Article • Journal of Virology, December 2010, ASM Journals

    Professor Nigel James Temperton

  238. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses

    Article • Virology, December 2010, Elsevier

    Professor Nigel James Temperton, James Wood

  239. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

    Article • Journal of Clinical Investigation, May 2010, American Society for Clinical Investigation

    Professor Nigel James Temperton

  240. Investigating original antigenic sin responses to H5N1 influenza viruses (92.19)

    Article • The Journal of Immunology, April 2010, The American Association of Immunologists

    Professor Nigel James Temperton

  241. The Use of Retroviral Pseudotypes for the Measurement of Antibody Responses to SARS Coronavirus

    Article • October 2009, Springer Science + Business Media

    Professor Nigel James Temperton

  242. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

    Article • Vaccine, October 2009, Elsevier

    Professor Nigel James Temperton

  243. Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1

    Article • Antiviral Research, September 2009, Elsevier

    Professor Nigel James Temperton

  244. Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses

    Article • Journal of Virological Methods, May 2009, Elsevier

    Professor Nigel James Temperton, Professor Paul KS Chan

  245. Retroviral Pseudotypes

    Article • March 2009, Wiley

    Professor Nigel James Temperton

  246. T Cell Responses to Whole SARS Coronavirus in Humans

    Article • The Journal of Immunology, October 2008, The American Association of Immunologists

    Professor Nigel James Temperton

  247. In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses

    Article • Antiviral Research, September 2008, Elsevier

    Professor Nigel James Temperton

  248. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison

    Article • Journal of General Virology, September 2008, Society for General Microbiology

    Professor Nigel James Temperton

  249. Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines

    Article • Journal of General Virology, June 2007, Society for General Microbiology

    Professor Nigel James Temperton

  250. A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies

    Article • Influenza and Other Respiratory Viruses, May 2007, Wiley

    Professor Nigel James Temperton

  251. The distribution of the endogenous retroviruses HERV-K113 and HERV-K115 in health and disease

    Article • Genomics, September 2005, Elsevier

    Professor Nigel James Temperton

  252. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

    Article • Emerging Infectious Diseases, March 2005, Centers for Disease Control and Prevention (CDC)

    Professor Nigel James Temperton, Professor Paul KS Chan

  253. Article • Arthritis Research, January 2005, Springer Science + Business Media

    Professor Nigel James Temperton

  254. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides

    Article • Journal of Medical Virology, March 2003, Wiley

    Professor Nigel James Temperton, Professor Vincent Emery

  255. DNA vaccines against cytomegalovirus: current progress

    Article • International Journal of Antimicrobial Agents, March 2002, Elsevier

    Professor Nigel James Temperton

  256. Distinct Mitochondrial and Cytosolic Enzymes Mediate Trypanothione-dependent Peroxide Metabolism in Trypanosoma cruzi

    Article • Journal of Biological Chemistry, March 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Nigel James Temperton

  257. Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocidal agents gentian violet and benznidazole

    Article • Molecular and Biochemical Parasitology, October 1998, Elsevier

    Professor Nigel James Temperton

  258. Cloning of an Fe-superoxide dismutase gene homologue from Trypanosoma cruzi

    Article • Molecular and Biochemical Parasitology, February 1996, Elsevier

    Professor Nigel James Temperton